Artelo Biosciences, Inc.

What they do

Artelo Biosciences is a clinical-stage biopharmaceutical company focused on developing therapeutics that target lipid-signaling modulation pathways, including the endocannabinoid system. Its lead programs include ART27.13, a dual CB1/CB2 agonist in a Phase 1b/2a trial for cancer-related anorexia, and ART26.12, a FABP5 inhibitor in Phase 1 for chemotherapy-induced peripheral neuropathy. The company also has ART12.11, a proprietary cocrystal of CBD and TMP, in nonclinical development. Artelo has in-licensed ART27.13 from NEOMED (now adMare Bioinnovations), which obtained rights from AstraZeneca.

Revenue drivers

• ART27.13 — Phase 1b/2a candidate for cancer anorexia; no approved treatment exists; potential revenue from future commercialization if approved.
• ART26.12 — Phase 1 candidate for CIPN with broader potential in cancer, pain, and anxiety; no current revenue.
• ART12.11 — Preclinical CBD cocrystal; no revenue expected near-term; patent protected until 2038.

Recent performance

For the year ended December 31, 2025, Artelo reported a net loss of $12.9 million, compared to a $9.8 million loss in 2024. Diluted EPS was -$37.75 in 2025 versus -$54.89 in 2024. Operating cash flow was -$8.5 million in 2025, slightly worse than -$8.3 million in 2024. The company had $4.2 million in cash as of June 30, 2026, with total assets of $6.5 million and shareholder equity of $5.0 million. The independent auditor included a going concern explanatory paragraph in the 2025 financial statements, citing recurring losses and net capital deficiency.

Strategy

Management's stated strategy is to advance its pipeline of lipid-signaling therapeutics, balancing risk across mechanisms and stages. Key priorities include completing the Phase 1b/2a CAReS trial for ART27.13 and progressing ART26.12 into later-stage studies for CIPN. The company is also exploring broader applications for its FABP inhibitor library. Artelo executed a 1-for-3 reverse stock split in March 2026 to maintain Nasdaq listing compliance.

Risks

• Going concern risk — The auditor's report raised substantial doubt about the company's ability to continue as a going concern, and management states it needs additional financing to support operations.
• Funding risk — The company has no approved products or revenue, and must raise capital to fund clinical trials and operations; financing may not be available on acceptable terms.
• Clinical and regulatory risk — ART27.13 and ART26.12 are in early-stage trials; failures in efficacy or safety could halt development, and regulatory requirements may change.
• Licensing and IP risk — ART27.13 is in-licensed, and failure to comply with license obligations could result in loss of rights vital to the business.

Outlook

Management is focused on advancing ART27.13 in the CAReS trial and ART26.12 following positive Phase 1 SAD results. The company expects to need additional funding to complete clinical trials and continues to explore financing and partnership opportunities. The going concern uncertainty signals the need for near-term capital raises.